Aytu BioScience Inc Net Assets
Aytu BioScience Inc net assets. Based on the latest financial reports, Aytu BioScience Inc (AYTU) has net assets worth $35.14 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($111.69 Million) and total liabilities ($76.55 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how fast is Aytu BioScience Inc growing its equity to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $35.14 Million |
| % of Total Assets | 31.47% |
| Annual Growth Rate | 46.84% |
| 5-Year Change | -86.21% |
| 10-Year Change | 88.06% |
| Growth Volatility | 344.0 |
Net Assets of Aytu BioScience Inc (2007–2025)
Net assets of Aytu BioScience Inc from 2007 to 2025. This chart illustrates how Aytu BioScience Inc's net assets have evolved over time, based on quarterly financial data. See Aytu BioScience Inc balance sheet quality to measure how much of total assets are equity-financed.
Annual Net Assets for Aytu BioScience Inc (2007–2025)
The table below shows the annual net assets of Aytu BioScience Inc from 2007 to 2025. For live market cap and overall valuation, see market value of Aytu BioScience Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $18.97 Million | -31.57% |
| 2024-06-30 | $27.72 Million | -29.58% |
| 2023-06-30 | $39.36 Million | -11.17% |
| 2022-06-30 | $44.31 Million | -67.79% |
| 2021-06-30 | $137.57 Million | +44.79% |
| 2020-06-30 | $95.02 Million | +1240.54% |
| 2019-06-30 | $7.09 Million | -47.20% |
| 2018-06-30 | $13.42 Million | +235.63% |
| 2017-06-30 | $4.00 Million | -60.34% |
| 2016-06-30 | $10.09 Million | -35.42% |
| 2015-06-30 | $15.62 Million | +190.84% |
| 2014-06-30 | $5.37 Million | +4943.59% |
| 2013-06-30 | $-110.86K | -59.01% |
| 2012-06-30 | $-69.72K | -95.86% |
| 2011-06-30 | $-35.59K | +35.99% |
| 2010-06-30 | $-55.61K | -309.39% |
| 2009-06-30 | $-13.58K | -152.33% |
| 2008-06-30 | $25.96K | +38.03% |
| 2007-06-30 | $18.81K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aytu BioScience Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 33339642800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Aytu BioScience Inc Net Assets Breakdown (June 2025)
Aytu BioScience Inc net assets breakdown by equity component as of June 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.01% |
| Other Components | $352.50 Million | 1858.59% |
| Total Equity | $18.97 Million | 100.00% |
Aytu BioScience Inc Competitors by Market Cap
The table below lists competitors of Aytu BioScience Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Korean Drug Co. Ltd
KQ:014570
|
$20.62 Million |
|
VACCITECH (SP.ADR)/1
F:2AB
|
$20.62 Million |
|
Pure Hydrogen Corporation Ltd
AU:PH2
|
$20.63 Million |
|
CU Medical Systems Inc
KQ:115480
|
$20.63 Million |
|
Zuleika Gold Ltd
AU:ZAG
|
$20.60 Million |
|
Food and Drinks Public Company Limited
BK:F&D
|
$20.60 Million |
|
MegaMD Co. Ltd
KQ:133750
|
$20.60 Million |
|
Zee Learn Limited
NSE:ZEELEARN
|
$20.59 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aytu BioScience Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 27,716,000 to 18,966,000, a change of -8,750,000 (-31.6%).
- Net loss of 13,562,000 reduced equity.
- New share issuances of 14,840,000 increased equity.
- Other factors decreased equity by 10,028,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-13.56 Million | -71.51% |
| Share Issuances | $14.84 Million | +78.25% |
| Other Changes | $-10.03 Million | -52.87% |
| Total Change | $- | -31.57% |
Book Value vs Market Value Analysis
This analysis compares Aytu BioScience Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.64x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.00x to 0.64x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-06-30 | $18806.00 | $1.92 | x |
| 2008-06-30 | $5191.60 | $1.92 | x |
| 2009-06-30 | $-2716.60 | $1.92 | x |
| 2010-06-30 | $-9268.00 | $1.92 | x |
| 2011-06-30 | $-4449.38 | $1.92 | x |
| 2012-06-30 | $-8714.75 | $1.92 | x |
| 2013-06-30 | $-13857.00 | $1.92 | x |
| 2014-06-30 | $596600.78 | $1.92 | x |
| 2015-06-30 | $1115460.86 | $1.92 | x |
| 2016-06-30 | $463263.80 | $1.92 | x |
| 2017-06-30 | $34330.24 | $1.92 | x |
| 2018-06-30 | $4033.77 | $1.92 | x |
| 2019-06-30 | $181.87 | $1.92 | x |
| 2020-06-30 | $420.50 | $1.92 | x |
| 2021-06-30 | $163.77 | $1.92 | x |
| 2022-06-30 | $30.14 | $1.92 | x |
| 2023-06-30 | $11.78 | $1.92 | x |
| 2024-06-30 | $5.00 | $1.92 | x |
| 2025-06-30 | $3.02 | $1.92 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aytu BioScience Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -71.51%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -20.43%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 6.55x
- Recent ROE (-71.51%) is above the historical average (-141.66%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -260.31% | 0.00% | 0.00x | 3.17x | $-50.83K |
| 2008 | -220.25% | 0.00% | 0.00x | 2.85x | $-59.77K |
| 2009 | 0.00% | -3365.37% | 0.04x | 0.00x | $-57.54K |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-54.71K |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-133.24K |
| 2012 | 0.00% | -3410.00% | 0.14x | 0.00x | $-52.70K |
| 2013 | 0.00% | -3275.31% | 0.18x | 0.00x | $-46.23K |
| 2014 | -103.90% | -9466.80% | 0.00x | 2.24x | $-6.12 Million |
| 2015 | -49.46% | -2950.32% | 0.01x | 1.17x | $-9.29 Million |
| 2016 | -279.42% | -1099.73% | 0.11x | 2.41x | $-29.19 Million |
| 2017 | -562.73% | -698.67% | 0.21x | 3.75x | $-22.91 Million |
| 2018 | -75.89% | -278.36% | 0.17x | 1.57x | $-11.53 Million |
| 2019 | -665.47% | -644.33% | 0.21x | 4.90x | $-47.88 Million |
| 2020 | -14.34% | -49.29% | 0.18x | 1.61x | $-23.12 Million |
| 2021 | -42.37% | -88.81% | 0.25x | 1.93x | $-72.05 Million |
| 2022 | -245.51% | -112.53% | 0.70x | 3.11x | $-113.21 Million |
| 2023 | -43.32% | -15.88% | 0.78x | 3.50x | $-20.99 Million |
| 2024 | -57.17% | -24.31% | 0.55x | 4.29x | $-18.62 Million |
| 2025 | -71.51% | -20.43% | 0.53x | 6.55x | $-15.46 Million |
Industry Comparison
This section compares Aytu BioScience Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $295,395,870
- Average return on equity (ROE) among peers: -40.64%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aytu BioScience Inc (AYTU) | $35.14 Million | -260.31% | 2.18x | $20.61 Million |
| Aurora Cannabis Inc (ACB) | $3.83 Million | -248.34% | 2.53x | $236.15 Million |
| ADC Therapeutics SA (ADCT) | $249.17 Million | -36.07% | 0.09x | $143.73 Million |
| Akanda Corp (AKAN) | $-11.99 Million | 0.00% | 0.00x | $540.73K |
| Akebia Ther (AKBA) | $104.08 Million | -35.58% | 0.07x | $186.10 Million |
| Alkermes Plc (ALKS) | $1.20 Billion | -13.13% | 0.49x | $7.70 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $340.61 Million | -58.24% | 0.15x | $3.28 Billion |
| Amphastar P (AMPH) | $329.25 Million | 3.20% | 0.30x | $980.07 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-186.87 Million | 0.00% | 0.00x | $5.92 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $896.36 Million | -18.93% | 3.86x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $26.71 Million | 0.65% | 0.08x | $273.01 Million |
About Aytu BioScience Inc
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release o… Read more